Adaptimmune Therapeutics Plc Stock Buy Hold or Sell Recommendation
| ADAP Stock | USD 0.45 0.01 2.17% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Adaptimmune Therapeutics Plc is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Adaptimmune Therapeutics Plc within the specified time frame.
Check out Adaptimmune Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Adaptimmune and provide practical buy, sell, or hold advice based on investors' constraints. Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Adaptimmune |
Execute Adaptimmune Therapeutics Buy or Sell Advice
The Adaptimmune recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Adaptimmune Therapeutics Plc. Macroaxis does not own or have any residual interests in Adaptimmune Therapeutics Plc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Adaptimmune Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Adaptimmune Therapeutics Trading Alerts and Improvement Suggestions
| Adaptimmune Therapeutics generated a negative expected return over the last 90 days | |
| Adaptimmune Therapeutics has some characteristics of a very speculative penny stock | |
| Adaptimmune Therapeutics has high historical volatility and very poor performance | |
| Adaptimmune Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 60.28 M. Net Loss for the year was (113.87 M) with profit before overhead, payroll, taxes, and interest of 31.87 M. | |
| Adaptimmune Therapeutics Plc currently holds about 199.67 M in cash with (140.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Acquisition by Tayton-martin Helen Katrina of 565416 shares of Adaptimmune Therapeutics at 0.0013 subject to Rule 16b-3 |
Adaptimmune Therapeutics Returns Distribution Density
The distribution of Adaptimmune Therapeutics' historical returns is an attempt to chart the uncertainty of Adaptimmune Therapeutics' future price movements. The chart of the probability distribution of Adaptimmune Therapeutics daily returns describes the distribution of returns around its average expected value. We use Adaptimmune Therapeutics Plc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Adaptimmune Therapeutics returns is essential to provide solid investment advice for Adaptimmune Therapeutics.
| Mean Return | -0.52 | Value At Risk | -6.25 | Potential Upside | 4.84 | Standard Deviation | 3.60 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Adaptimmune Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Adaptimmune Stock Institutional Investors
The Adaptimmune Therapeutics' institutional investors refer to entities that pool money to purchase Adaptimmune Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Fmr Inc | 2024-12-31 | 1.8 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.3 M | Jpmorgan Chase & Co | 2024-12-31 | 916.9 K | Redmile Group, Llc | 2024-12-31 | 715.6 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 529.1 K | Rathbone Brothers Plc | 2024-12-31 | 432.8 K | State Street Corp | 2024-12-31 | 400.1 K | Jane Street Group Llc | 2024-12-31 | 326.9 K | Key Client Fiduciary Advisors, Llc | 2024-12-31 | 255.4 K | Ecor1 Capital, Llc | 2024-12-31 | 27.4 M | Long Focus Capital Management, Llc | 2024-12-31 | 20.5 M |
Adaptimmune Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 6.6M | 90.2M | (42.1M) | 37.4M | 33.7M | 24.0M | |
| Free Cash Flow | (56.5M) | 1.9M | (171.5M) | (145.8M) | (131.2M) | (124.6M) | |
| Depreciation | 7.6M | 6.6M | 6.1M | 9.5M | 10.9M | 11.4M | |
| Other Non Cash Items | (55K) | 1.2M | 903K | (23.2M) | (20.9M) | (19.8M) | |
| Capital Expenditures | 2.9M | 8.8M | 29.7M | 4.9M | 5.6M | 9.5M | |
| Net Income | (130.1M) | (158.1M) | (165.5M) | (113.9M) | (102.5M) | (107.6M) | |
| End Period Cash Flow | 61.5M | 151.7M | 109.6M | 147.0M | 169.1M | 124.3M | |
| Investments | (276.0M) | 84.6M | 89.1M | 176.5M | 203.0M | 213.2M | |
| Change To Netincome | 11.9M | 9.0M | 22.3M | 19.1M | 22.0M | 12.8M | |
| Change To Inventory | (5.7M) | 15.1M | 5.4M | (1.0) | (1.15) | (1.09) |
Adaptimmune Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Adaptimmune Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Adaptimmune Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Adaptimmune stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.43 | |
β | Beta against Dow Jones | 0.85 | |
σ | Overall volatility | 3.53 | |
Ir | Information ratio | -0.12 |
Adaptimmune Therapeutics Volatility Alert
Adaptimmune Therapeutics Plc exhibits very low volatility with skewness of 1.04 and kurtosis of 3.98. Adaptimmune Therapeutics Plc is a potential penny stock. Although Adaptimmune Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Adaptimmune Therapeutics Plc. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Adaptimmune instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Adaptimmune Therapeutics Fundamentals Vs Peers
Comparing Adaptimmune Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Adaptimmune Therapeutics' direct or indirect competition across all of the common fundamentals between Adaptimmune Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Adaptimmune Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Adaptimmune Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Adaptimmune Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Adaptimmune Therapeutics to competition |
Note: Acquisition by Tayton-martin Helen Katrina of 565416 shares of Adaptimmune Therapeutics at 0.0013 subject to Rule 16b-3 [view details]
Adaptimmune Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Adaptimmune . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Adaptimmune Therapeutics Buy or Sell Advice
When is the right time to buy or sell Adaptimmune Therapeutics Plc? Buying financial instruments such as Adaptimmune Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Adaptimmune Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Office Supplies Thematic Idea Now
Office Supplies
Companies producing and selling office supplies, and accessories. The Office Supplies theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Office Supplies Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.